First-Line Medications for Systemic Lupus Erythematosus
Hydroxychloroquine is the universal first-line medication for all patients with SLE and should be started immediately upon diagnosis, regardless of disease severity. 1, 2, 3
Core First-Line Treatment Algorithm
Universal Baseline Therapy
Glucocorticoids: Use Minimally and Temporarily
- Low-dose prednisone (≤5 mg/day maintenance maximum) 1, 2
- Use only as a bridge therapy while waiting for immunosuppressives to take effect
- The 2024 EULAR guidelines lowered the maximum maintenance dose from 7.5 mg/day to 5 mg/day based on observational data showing increased adverse events above this threshold 1
- Chronic glucocorticoid use correlates with infections, osteonecrosis, and irreversible organ damage 1
- Goal: minimize duration and taper to discontinuation whenever possible 2
Adding Immunosuppressive Therapy Early
For Mild-to-Moderate Disease
After HCQ, if disease activity persists:
- Methotrexate or Azathioprine as conventional immunosuppressants 3, 4
- These have steroid-sparing properties and allow faster glucocorticoid discontinuation 5
For Moderate-to-Severe Extrarenal Disease
- Mycophenolate mofetil (MMF) 3
- Belimumab (anti-BAFF monoclonal antibody) - FDA-approved biologic with high-quality RCT evidence 1, 3
- Anifrolumab (anti-type 1 interferon receptor) - FDA-approved with robust RCT data showing organ-specific improvements 1, 3
The 2025 ACR guideline emphasizes early introduction of conventional and/or biologic immunosuppressive therapies rather than prolonged glucocorticoid monotherapy 2. The 2024 EULAR review confirms that approved biologics (belimumab and anifrolumab) have proven efficacy through high-quality RCTs with low risk of bias 1.
Treatment Target
Aim for remission or Low Lupus Disease Activity State (LLDAS) 1, 2
- Both states are associated with lower risk for organ damage, flares, mortality, and hospitalization 1
- Remission shows slightly lower odds for damage accrual compared to LLDAS, but LLDAS is achieved more frequently 1
- This means minimal symptoms, low autoimmune inflammatory markers, and minimal-to-no systemic glucocorticoids while on maintenance immunomodulatory therapy 3
Critical Pitfalls to Avoid
- Never delay HCQ initiation - it reduces mortality and should start at diagnosis 1, 3
- Don't rely on glucocorticoids long-term - they cause more harm than benefit beyond short-term disease control 1, 2
- Don't wait for severe organ damage before adding immunosuppressives - early aggressive therapy prevents irreversible damage 2
- Monitor HCQ retinal toxicity - risk increases with longer duration and higher cumulative dose, though actual rates vary by screening method 1
The evidence strongly converges: HCQ universally, glucocorticoids minimally and temporarily, and early immunosuppressive therapy (conventional or biologic) to achieve disease control while minimizing medication toxicity. 1, 2, 3